Maa: Australia
Kieli: englanti
Lähde: Department of Health (Therapeutic Goods Administration)
lisinopril dihydrate
Sun Pharma ANZ Pty Ltd
Lisinopril dihydrate
Registered
Lisinopril Ranbaxy CMI V1 Feb 2009 Page 1 LISINOPRIL RANBAXY LISINOPRIL DIHYDRATE_ _ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about LISINOPRIL RANBAXY. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking LISINOPRIL RANBAXY against the benefits it is expected to have for you. IF YOU HAVE ANY CONCERNS ABOUT TAKING THIS MEDICINE, ASK YOUR DOCTOR OR PHARMACIST. KEEP THIS LEAFLET WITH THE MEDICINE. You may need to read it again. WHAT LISINOPRIL RANBAXY IS USED FOR LISINOPRIL RANBAXY_ _is used to: lower high blood pressure (hypertension) treat heart failure treat patients who have just had a heart attack HYPERTENSION: Everyone has blood pressure. This pressure helps get your blood all around your body. Your blood pressure may be different at different times of the day, depending on how busy or worried you are. You have hypertension (high blood pressure) when your blood pressure stays higher than is needed, even when you are calm and relaxed. There are usually no symptoms of hypertension. The only way of knowing that you have hypertension is to have your blood pressure checked on a regular basis. If high blood pressure is not treated it can lead to serious health problems, including stroke, heart disease and kidney failure. LISINOPRIL RANBAXY is used to lower high blood pressure (hypertension). HEART FAILURE: Heart failure means that the heart muscle cannot pump blood strongly enough to supply all the blood needed throughout the body. Heart failure is not the same as heart attack and does not mean that the heart stops working. Heart failure may start off with no symptoms, but as the condition progresses, people may feel short of breath or may get tired easily after light physical activity such as walking. Some people may wake up short of breath at night. Fluid may collect in different parts of the body Lue koko asiakirja
LISINOPRIL RANBAXY PI V1 Apr 09 Page 1 LISINOPRIL RANBAXY TABLETS NAME OF THE DRUG Active Ingredient:_ _ Lisinopril dihydrate. Inactive Ingredients: Mannitol, calcium hydrogen phosphate, Maize starch, Pregelatinised maize starch, magnesium stearate. All strengths also contain iron oxide yellow (CI77492), while the 20 mg tablet also contains iron oxide red (CI77491) DESCRIPTION Chemical Name: _N_-[_N_-[(1_S_)-1-carboxy-3-phenylpropyl]-L-lysyl]-L-proline dihydrate Chemical Structure: _ _ _ _ _ _ _ _ Molecular Formula: C 21 H 31 N 3 O 5 .2H 2 O Molecular Weight: 441.53 CAS Number: 83915-83-7_ _ A synthetic peptide derivative, lisinopril dihydrate is an oral long-acting angiotensin converting enzyme inhibitor. It is a lysine analogue of enalaprilat (active metabolite of enalapril). Lisinopril dihydrate is a white to off-white crystalline powder that is soluble in water, sparingly soluble in methanol and practically insoluble in ethanol. PHARMACOLOGY MECHANISM OF ACTION_ _ Lisinopril is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin converting enzyme (ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor substance, angiotensin ll. Angiotensin ll also stimulates aldosterone secretion by the adrenal cortex. Inhibition of ACE results in decreased concentrations of plasma angiotensin ll which results in decreased vasopressor activity and to decreased aldosterone secretion. The latter decrease may result in a small increase of serum potassium. In hypertensive patients with normal renal function treated with lisinopril alone for up to 24 weeks, the mean increase in serum potassium was approximately 0.1 mmol/L; however, approximately 15% of patients had increases greater than 0.5 mmol/L and approximately 6% had a decrease greater than 0.5 mmol/L. In the same study, patients treated with lisinopril and hydrochlorothiazide for up to 24 weeks had a mean decrease in serum potassium of 0.1 mmol/L; approximately 4% of patients had increases greater than 0.5 mmol/L and approximately 12% had a N N Lue koko asiakirja